OKYO Pharma (OKYO)

• Market cap: $80.6M
• 1 day: -2.55%
• 5 days: -6.71%
• 1 month: -4.97%
• 3 months: -8.93%
• 6 months: -20.31%
• Year to date: -31.39%
• 1 year: -50.32%
• 5 years: -57.73%
• 10 years: -57.73%
• Sector: Healthcare
• Industry: Biotechnology

About: OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

Employees: 5